Data presented SITC (Society for Immunotherapy of Cancer) not only further supports eilagimod alpha ("ei") efficacy in metastac breast ("mBC") and head and neck ("HNSCC") cancers, but also highlights a potenal central role for ei across cancer therapy. Interim overall survival (“OS”) from the AIPAC was already posive, this final data is slightly improved with a clear 2.9 month increase in OS with ei+ paclitaxel. While this was not stascally significant, there was a significant increase ....
17 Nov 2021
Data highlights efti efficacy and potential central role in cancer therapy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Data highlights efti efficacy and potential central role in cancer therapy
Data presented SITC (Society for Immunotherapy of Cancer) not only further supports eilagimod alpha ("ei") efficacy in metastac breast ("mBC") and head and neck ("HNSCC") cancers, but also highlights a potenal central role for ei across cancer therapy. Interim overall survival (“OS”) from the AIPAC was already posive, this final data is slightly improved with a clear 2.9 month increase in OS with ei+ paclitaxel. While this was not stascally significant, there was a significant increase ....